ANNAPOLIS, Md. , March 14, 2017 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the year ended December 31, 2016 . Fourth quarter and subsequent operational

ANNAPOLIS, Md. , March 13, 2017 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, announced today that it has established a record date and meeting date for a special meeting of stockholders to vote upon, among other

ANNAPOLIS, Md. and GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) and Altimmune, Inc. , a privately-held immunotherapeutics company targeting infectious diseases, announced today the signing of a definitive agreement for the merger of PharmAthene and

Final Payment of $83.9 Million Received from SIGA of $217 Million Total Judgment ANNAPOLIS, Md. , Nov. 17, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that its Board of Directors has declared a

- Award amount totals $217 million - ANNAPOLIS, Md. , Nov. 16, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today received a final payment from SIGA Technologies, Inc.

ANNAPOLIS, Md. , Nov. 4, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the third quarter of 2016.  PharmAthene received $122.5 million from SIGA

ANNAPOLIS, Md. , Sept. 16, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced it has received a series of payments from SIGA Technologies, Inc. totaling $90 million over the past month.  Combined with

ANNAPOLIS, Md. , Aug. 25, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that after discussions with the Biomedical Advanced Research and Development Authority (BARDA) the Company has withdrawn the

ANNAPOLIS, Md. , Aug. 5, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today filed a formal protest against the Department of Health and Human Services , challenging its solicitation for a next-generation Anthrax

ANNAPOLIS, Md. , Aug. 4, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the second quarter of 2016.  Under SIGA's Reorganization Plan, approved by U.S.